Accelerating Timelines

A Phase III, double-blind, parallel-group dermatology study enrolled 681 patients at 90 sites across North America. Its purpose: to assess the efficacy and safety of a new treatment for papulopustular rosacea. The sponsor originally asked us to complete enrollment in eight months, but because it needed to beat a competitor to registration, it shortened the timeline to six months. By assembling a team that could work independently and knew how to coordinate clinical operations and data verification, we met the compressed schedule.

Phone Us Now
Email Us Now